公开(公告)号：US11145417B2

公开(公告)日：2021-10-12

申请号：US15116202

申请日：2015-02-04

申请人： OPTIMATA LTD.

发明人： Yuri Kheifetz ,  Yuri Kogan ,  Itamar Sela ,  Zvia Agur

IPC分类号： G16H50/50 ,  G16H50/20 ,  G16H20/10 ,  G06Q50/00

摘要： A computerized system and method for planning a medical treatment for an individual under specific medical condition comprises a data input utility configured for receiving input data, and a data processor. The input data includes first input data comprising medical data of a specific individual, and second input data comprising data indicative of at least one endpoint of treatment. The data processor is configured for utilizing the medical data of the specific individual and the data indicative of the at least one endpoint and processing data indicative of disease progression models, each disease progression model corresponding to a treatment plan comprising one or more predetermined treatment protocols for treating the specific medical condition. The data processor generates output data indicative of a treatment effect on the individual with respect to each of the treatment plans and at least one endpoint to evaluate the treatment plans.

公开(公告)号：US20110286960A1

公开(公告)日：2011-11-24

申请号：US13126929

申请日：2009-11-02

申请人： Oded Vainas ,  Vladimir Vainstein ,  Ori Inbar ,  Marina Kleiman ,  Radel Ben-av ,  Zvia Agur

发明人： Oded Vainas ,  Vladimir Vainstein ,  Ori Inbar ,  Marina Kleiman ,  Radel Ben-av ,  Zvia Agur

IPC分类号： A61K38/19 ,  A61P37/00 ,  G06G7/60 ,  A61P35/00

CPC分类号： A61K45/06 ,  A61K38/193 ,  G16C20/30 ,  A61K2300/00

摘要： Neutropenia is the dose-limiting toxicity of the tri-weekly docetaxel (Taxotere®) schedule. Here, we evaluate in Metastatic Breast Cancer (MBC) patients (N=38) a computerized method for predicting docetaxel-induced neutropenia, and use the model to identify improved docetaxel and Granulocyte Colony Stimulating Factor (G-CSF) regimens. Pharmacokinetics/pharmacodynamics (PK/PD) models were created and simulated concomitantly with a mathematical granulopoiesis model. Individual baseline neutrophil counts and docetaxel schedules served as inputs. Our trial validated the model accuracy in predicting nadir timings (r=0.99), grade 3/4 neutropenia (86% success) and neutrophil profiles (r=0.62). Model was robust to CYP3A-induced variability, except for slightly less accurate grade 3/4 neutropenia predictions. Simulations confirm smaller toxicity of the weekly docetaxel regimen than the tri-weekly one, and suggest an optimal G-CSF support for alleviating neutropenia, 60 μg/day QD×3, 6-7 days post-docetaxel, administered tri- and bi-weekly, and 4 days post weekly docetaxel>33 mg/m2.

摘要翻译： 中性粒细胞减少是三周多西他赛（Taxotere®）计划的剂量限制性毒性。 在这里，我们评估转移性乳腺癌（MBC）患者（N = 38）一种预测多西紫杉醇诱导的中性粒细胞减少的计算机化方法，并使用该模型来鉴定改良的多西他赛和粒细胞集落刺激因子（G-CSF）方案。 药物动力学/药效学（PK / PD）模型被创建并模拟与数学粒子学模型。 单个基线嗜中性粒细胞计数和多西他赛计划作为输入。 我们的试验验证了模型准确性预测最低点时间（r = 0.99），3/4级中性粒细胞减少（86％成功）和嗜中性粒细胞分布（r = 0.62）。 模型对CYP3A诱导的变异性是稳健的，除了稍微不太准确的3/4级中性粒细胞减少预测。 模拟证实每周多西紫杉醇方案的毒性小于三周一次，并建议最佳的G-CSF支持减轻中性粒细胞减少，60μg/天QD×3,6-天后多西紫杉醇，给予三 - 和二 - 每周，每周多西紫杉醇> 33 mg / m2。

公开(公告)号：US07133814B2

公开(公告)日：2006-11-07

申请号：US09827229

申请日：2001-04-06

申请人： Zvia Agur ,  Sarel Fleishmann ,  Kirill Skomorovski ,  Moshe Vardi

发明人： Zvia Agur ,  Sarel Fleishmann ,  Kirill Skomorovski ,  Moshe Vardi

IPC分类号： G06N3/00 ,  G06G7/60

CPC分类号： G06F19/3481 ,  G06F19/00 ,  G16H50/50

摘要： A system for modeling thrombopoietic lineage in an individual is presented. The system comprises a thrombopoiesis system model including a process progression model, for cells involved in thrombopoiesis, said progression model including multiplication and differentiation. It further comprises a system model modifier, wherein said thrombopoiesis system model is modified by the system model modifier based on parameters specific to the individual. In addition to modifying an individual's thrombopoietic process, the system can be modified to portray different pathological scenarios as well as different scenarios of response to treatment.

摘要翻译： 提出了一种用于建模个体血小板生成谱系统。 该系统包括血小板生成系统模型，其包括涉及血小板生成的细胞的过程进展模型，所述进展模型包括增殖和分化。 其还包括系统模型修改器，其中所述血小板生成系统模型由系统模型修改器基于个体特有的参数来修改。 除了修改个体的血小板生成过程之外，还可以修改系统来描绘不同的病理情景以及对治疗反应的不同场景。

公开(公告)号：US08489336B2

公开(公告)日：2013-07-16

申请号：US12621175

申请日：2009-11-18

申请人： Levon Arakelyan ,  Vera Selitser ,  Zvia Agur ,  Tali Eilam Tzoreff

发明人： Levon Arakelyan ,  Vera Selitser ,  Zvia Agur ,  Tali Eilam Tzoreff

IPC分类号： G06F19/00

CPC分类号： G06F19/704

摘要： A method for repurposing a pharmaceutical compound. The method includes identifying a pharmaceutical compound, the pharmaceutical compound corresponding to a drug that has failed in clinical development or an approved drug. A mathematical model describing the physiological processes related to at least one disease and the effects of the pharmaceutical compound on the disease is created. The model is adjusted based upon information from preclinical or clinical trials. A new treatment protocol is suggested to salvage the failed drug or a new way to use an approved drug. The suggested treatment protocol is displayed. Systems and computer program products encompassing the above techniques are also disclosed.

摘要翻译： 一种再利用药物化合物的方法。 该方法包括鉴定药物化合物，对应于临床开发失败的药物的药物化合物或批准的药物。 产生描述与至少一种疾病相关的生理过程和药物化合物对疾病的影响的数学模型。 该模型根据临床前或临床试验的信息进行调整。 建议采用新的治疗方案来挽救失败的药物或使用批准药物的新方法。 显示建议的治疗方案。 还公开了包括上述技术的系统和计算机程序产品。

公开(公告)号：US07970550B2

公开(公告)日：2011-06-28

申请号：US10662345

申请日：2003-09-16

申请人： Levon Arakelyan ,  Vera Selitser ,  Zvia Agur

发明人： Levon Arakelyan ,  Vera Selitser ,  Zvia Agur

IPC分类号： G06F19/00

CPC分类号： G06F19/704 ,  G06F19/00 ,  G06F19/3456 ,  G06Q50/22 ,  G16H10/20 ,  G16H50/50

摘要： A method of performing interactive clinical trials for testing a new drug. A pre-clinical phase is performed in which a computer model for pharmacokinetics and pharmacodynamics of the drug is created and adjusted based on in vitro studies and in vivo studies in animals. A phase I clinical research is performed in which a clinical trial on at least a single dose is performed in parallel with performing computer simulation studies using the computer model. An optimal protocol is determined for the most responsive patient populations and indications for a phase II clinical trial. Phase II clinical trial is performed where a number of small scale clinical trials are performed in parallel based on results of the above. Phase III clinical research is performed for chosen indications by chosen protocols. Phase IV studies are performed for post-marketing subpopulation analysis and long term product safety assessment.

摘要翻译： 执行交互式临床试验以测试新药的方法。 进行临床前阶段，其中基于动物的体外研究和体内研究，创建并调整药物的药代动力学和药效学计算机模型。 进行I期临床研究，其中使用计算机模型进行与至少一个剂量的临床试验并行执行计算机模拟研究。 确定最有反应的患者群体的最佳方案和II期临床试验的适应症。 基于上述结果，进行了多次小规模临床试验并行进行II期临床试验。 通过选择的方案对选定的指示进行III期临床研究。 进行第四阶段研究，进行营销后人群分析和长期产品安全评估。

公开(公告)号：US06871171B1

公开(公告)日：2005-03-22

申请号：US09691053

申请日：2000-10-19

申请人： Zvia Agur ,  Sarel Fleishmann ,  Kirill Skomorovski ,  Moshe Vardi

发明人： Zvia Agur ,  Sarel Fleishmann ,  Kirill Skomorovski ,  Moshe Vardi

IPC分类号： A61B5/00 ,  A61K45/06 ,  A61P43/00 ,  G01N20060101 ,  G01N33/48 ,  G01N33/50 ,  G06F19/00 ,  G06N3/00

CPC分类号： G06F19/3481 ,  G06F19/00 ,  G16H50/50

摘要： Systems for recommending an optimal treatment protocol for a specific individual are disclosed. The systems comprise generally a system model, a plurality of treatment protocols, a system model modifier, wherein said system model is modified by the system model modifier based on parameters specific to the individual; and a selector to select an optimal treatment protocol from said plurality of treatment protocols based on the modified system model. Systems embodying the above techniques but for a general patient are also disclosed. Systems for a general patient and an individual for various specific diseases are disclosed. Methods and computer program products embodying the above techniques are also disclosed.

摘要翻译： 公开了为特定个体推荐最佳治疗方案的系统。 系统通常包括系统模型，多个处理协议，系统模型修改器，其中所述系统模型由系统模型修改器基于个体特有的参数来修改; 以及选择器，用于基于所述修改的系统模型从所述多个处理协议中选择最佳处理协议。 还公开了体现上述技术但是对于一般患者的系统。 公开了一般患者和个体用于各种特定疾病的系统。 还公开了体现上述技术的方法和计算机程序产品。

公开(公告)号：US08504303B2

公开(公告)日：2013-08-06

申请号：US13531698

申请日：2012-06-25

申请人： Zvia Agur ,  Sarel Fleishmann ,  Kirill Skomorovski ,  Moshe Vardi

发明人： Zvia Agur ,  Sarel Fleishmann ,  Kirill Skomorovski ,  Moshe Vardi

IPC分类号： G01N33/48 ,  G01N31/00 ,  G06G7/48 ,  G06G7/58

CPC分类号： G06F19/3481 ,  G06F19/00 ,  G16H50/50

摘要： System for recommending an optimal treatment protocol for a specific individual are disclosed. The systems comprise generally a system model, a plurality of treatment protocols, a system model modifier, wherein said system model is modified by the system model modifier based on parameters specific to the individual; and a selector to select an optimal treatment protocol from said plurality of treatment protocols based on the modified system model. Systems embodying the above techniques but for a general patient are also disclosed. Systems for a general patient and an individual for various specific diseases are disclosed. Methods and computer program products embodying the above techniques are also disclosed.

摘要翻译： 公开了为特定个体推荐最佳治疗方案的系统。 系统通常包括系统模型，多个处理协议，系统模型修改器，其中所述系统模型由系统模型修改器基于个体特有的参数来修改; 以及选择器，用于基于所述修改的系统模型从所述多个处理协议中选择最佳处理协议。 还公开了体现上述技术但是对于一般患者的系统。 公开了一般患者和个体用于各种特定疾病的系统。 还公开了体现上述技术的方法和计算机程序产品。

公开(公告)号：US20120284005A1

公开(公告)日：2012-11-08

申请号：US13531698

申请日：2012-06-25

申请人： Zvia AGUR ,  Sarel FLEISHMANN ,  Kirill SKOMOROVSKI ,  Moshe VARDI

发明人： Zvia AGUR ,  Sarel FLEISHMANN ,  Kirill SKOMOROVSKI ,  Moshe VARDI

IPC分类号： A61K45/06 ,  G06F19/12 ,  A61B5/00

CPC分类号： G06F19/3481 ,  G06F19/00 ,  G16H50/50

摘要： System for recommending an optimal treatment protocol for a specific individual are disclosed. The systems comprise generally a system model, a plurality of treatment protocols, a system model modifier, wherein said system model is modified by the system model modifier based on parameters specific to the individual; and a selector to select an optimal treatment protocol from said plurality of treatment protocols based on the modified system model. Systems embodying the above techniques but for a general patient are also disclosed. Systems for a general patient and an individual for various specific diseases are disclosed. Methods and computer program products embodying the above techniques are also disclosed.

摘要翻译： 公开了为特定个体推荐最佳治疗方案的系统。 系统通常包括系统模型，多个处理协议，系统模型修改器，其中所述系统模型由系统模型修改器基于个体特有的参数来修改; 以及选择器，用于基于所述修改的系统模型从所述多个处理协议中选择最佳处理协议。 还公开了体现上述技术但是对于一般患者的系统。 公开了一般患者和个体用于各种特定疾病的系统。 还公开了体现上述技术的方法和计算机程序产品。

公开(公告)号：US20100161301A1

公开(公告)日：2010-06-24

申请号：US12621175

申请日：2009-11-18

申请人： Levon ARAKELYAN ,  Vera Selitser ,  Zvia Agur ,  Tali Eilam Tzoreff

发明人： Levon ARAKELYAN ,  Vera Selitser ,  Zvia Agur ,  Tali Eilam Tzoreff

IPC分类号： G06G7/60

CPC分类号： G06F19/704

摘要： A method for repurposing a pharmaceutical compound. The method includes identifying a pharmaceutical compound, the pharmaceutical compound corresponding to a drug that has failed in clinical development or an approved drug. A mathematical model describing the physiological processes related to at least one disease and the effects of the pharmaceutical compound on the disease is created. The model is adjusted based upon information from preclinical or clinical trials. A new treatment protocol is suggested to salvage the failed drug or a new way to use an approved drug. The suggested treatment protocol is displayed. Systems and computer program products encompassing the above techniques are also disclosed.

摘要翻译： 一种再利用药物化合物的方法。 该方法包括鉴定药物化合物，对应于临床开发失败的药物的药物化合物或批准的药物。 产生描述与至少一种疾病相关的生理过程和药物化合物对疾病的影响的数学模型。 该模型根据临床前或临床试验的信息进行调整。 建议采用新的治疗方案来挽救失败的药物或使用批准药物的新方法。 显示建议的治疗方案。 还公开了包括上述技术的系统和计算机程序产品。

公开(公告)号：US20170140109A1

公开(公告)日：2017-05-18

申请号：US15116202

申请日：2015-03-04

申请人： OPTIMATA LTD.

发明人： Yuri KHEIFETZ ,  Yuri KOGAN ,  Itamar SELA ,  Zvia AGUR

IPC分类号： G06F19/00

CPC分类号： G06F19/325 ,  G06F19/321 ,  G06F19/3456 ,  G06Q50/22 ,  G16H50/20 ,  G16H50/50

摘要： A computerized system and method for planning a medical treatment for an individual under specific medical condition comprises a data input utility configured for receiving input data, and a data processor. The input data includes first input data comprising medical data of a specific individual, and second input data comprising data indicative of at least one endpoint of treatment. The data processor is configured for utilizing the medical data of the specific individual and the data indicative of the at least one endpoint and processing data indicative of disease progression models, each disease progression model corresponding to a treatment plan comprising one or more predetermined treatment protocols for treating the specific medical condition. The data processor generates output data indicative of a treatment effect on the individual with respect to each of the treatment plans and at least one endpoint to evaluate the treatment plans.